Background: The COVID-19 pandemic placed hospital workers at the front line of viral exposure, raising critical questions about the magnitude and durability of vaccine-induced humoral immunity in this population. Limited data are available on the serological response to SARS-CoV-2 vaccines among health-care workers in sub-Saharan Africa, particularly in Senegal where the AstraZeneca and Sinopharm vaccines were the main platforms deployed. Objective: To assess the serological profile of SARS-CoV-2 IgG antibodies in vaccinated and unvaccinated staff of the Idrissa Pouye General Hospital (HOGIP) in Dakar, Senegal, and to identify epidemiological factors associated with anti-RBD IgG seropositivity. Methods: A descriptive and analytical study was conducted from January 2022 to January 2023, enrolling 61 hospital workers (52 vaccinated with at least two doses of the COVID-19 vaccine AstraZeneca or Sinopharm COVID-19 vaccine; 9 unvaccinated controls). Quantitative anti-SARS-CoV-2 IgG antibodies targeting the receptor-binding domain (RBD) of the spike protein were measured by chemiluminescent microparticle immunoassay (CMIA, AdviseDx SARS-CoV-2 IgG II, Abbott) on the ARCHITECT ci4100 analyzer anti-RBD IgG seropositivity was defined as an IgG titer ≥ 50 AU/mL. Non-parametric tests (Mann-Whitney, Kruskal-Wallis, Spearman) were used; p < 0.05 was considered significant. Results: anti-RBD IgG seropositivity was observed in 98% of vaccinated participants and 100% of unvaccinated participants. Median IgG titers were 4671.8 AU/mL with AstraZeneca, 3177.5 AU/mL with Sinopharm and 1408 AU/mL in unvaccinated controls. Vaccination status (p < 0.05) and age (Spearman ρ = 0.39, p = 0.002) were the only factors significantly associated with antibody titers. Sex, comorbidities, vaccine type and inter-dose interval had no significant effect. Conclusion: Hospital workers at HOGIP showed high humoral immunity to SARS-CoV-2 regardless of vaccination, suggesting widespread occult exposure on top of vaccine-induced responses. Vaccination and age were the main determinants of antibody titers.
References
[1]
Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z., et al. (2020) A New Coronavirus Associated with Human Respiratory Disease in China. Nature, 579, 265-269. https://doi.org/10.1038/s41586-020-2008-3
[2]
WHO (2020) WHO Director-General’s Opening Remarks at the Media Briefing on COVID19—21 August 2020. https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---21-august-2020
[3]
World Health Organization, Regional Office for Africa (2020) Senegal Reports First COVID-19 Case. https://www.afro.who.int/news/senegal-reports-first-covid-19-case
[4]
Lim, R.H.F., Htun, H.L., Li, A.L., Guo, H., Kyaw, W.M., Hein, A.A., et al. (2022) Fending off Delta—Hospital Measures to Reduce Nosocomial Transmission of Covid-19. InternationalJournalofInfectiousDiseases, 117, 139-145. https://doi.org/10.1016/j.ijid.2022.01.069
[5]
Reinig, S. and Shih, S. (2024) Non-Neutralizing Functions in Anti-SARS-CoV-2 IgG Antibodies. BiomedicalJournal, 47, Article ID: 100666. https://doi.org/10.1016/j.bj.2023.100666
[6]
World Health Organization (2020) Laboratory Testing Strategy Recommendations for COVID-19: Interim Guidance. https://www.who.int/publications/i/item/laboratory-testing-strategy-recommendations-for-covid-19-interim-guidance
[7]
Xia, S., Zhang, Y., Wang, Y., Wang, H., Yang, Y., Gao, G.F., et al. (2021) Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial. TheLancetInfectiousDiseases, 21, 39-51. https://doi.org/10.1016/s1473-3099(20)30831-8
[8]
Voysey, M., Clemens, S.A.C., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., et al. (2021) Safety and Efficacy of the Chadox1 Ncov-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. TheLancet, 397, 99-111. https://doi.org/10.1016/s0140-6736(20)32661-1
[9]
Jackson-Thompson, B.M., Goguet, E., Laing, E.D., Olsen, C.H., Pollett, S., Hollis-Perry, K.M., et al. (2021) Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study: An Observational Cohort Study of SARS-CoV-2 Infection and Vaccination in Healthcare Workers. BMCInfectiousDiseases, 21, Article No. 544. https://doi.org/10.1186/s12879-021-06233-1
[10]
Lebbar, Z., Mahmoud, M., Yahyaoui, G. and Kouara, S. (2024) Seroprevalence of Anti-SARS-CoV-2 Antibodies in Hospital Staff before and after Vaccination at the Hassan II University Hospital in Fez. CahiersSantéMédecineThérapeutique, 33, 333-338. https://doi.org/10.1684/sanmt.2024.293
[11]
Kellam, P. and Barclay, W. (2020) The Dynamics of Humoral Immune Responses Following SARS-CoV-2 Infection and the Potential for Reinfection. JournalofGeneralVirology, 101, 791-797. https://doi.org/10.1099/jgv.0.001439
[12]
Lou, B., Li, T., Zheng, S., Su, Y., Li, Z., Liu, W., et al. (2020) Serology Characteristics of SARS-CoV-2 Infection after Exposure and Post-Symptom Onset. EuropeanRespiratoryJournal, 56, Article ID: 2000763. https://doi.org/10.1183/13993003.00763-2020
[13]
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., et al. (2020) Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease 2019. ClinicalInfectiousDiseases, 71, 2027-2034. https://doi.org/10.1093/cid/ciaa344
[14]
Mansour Ghanaie, R., Jamee, M., Khodaei, H., Shirvani, A., Amirali, A., Karimi, A., et al. (2023) Assessment of Early and Post COVID-19 Vaccination Antibody Response in Healthcare Workers: A Multicentre Cross-Sectional Study on Inactivated, mRNA and Vector-Based Vaccines. EpidemiologyandInfection, 151, e12. https://doi.org/10.1017/s0950268822001984
[15]
Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., et al. (2020) Effect of an Inactivated Vaccine against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA, 324, 951-960. https://doi.org/10.1001/jama.2020.15543
[16]
Voysey, M., Costa Clemens, S.A., Madhi, S.A., Weckx, L.Y., Folegatti, P.M., Aley, P.K., et al. (2021) Single-Dose Administration and the Influence of the Timing of the Booster Dose on Immunogenicity and Efficacy of ChAdOx1 nCOV-19 (AZD1222) Vaccine: A Pooled Analysis of Four Randomised Trials. TheLancet, 397, 881-891. https://doi.org/10.1016/s0140-6736(21)00432-3
[17]
Folegatti, P.M., Ewer, K.J., Aley, P.K., Angus, B., Becker, S., Belij-Rammerstorfer, S., et al. (2020) Safety and Immunogenicity of the ChAdOx1 nCOV-19 Vaccine against SARS-CoV-2: A Preliminary Report of a Phase 1/2, Single-Blind, Randomised Controlled Trial. TheLancet, 396, 467-478. https://doi.org/10.1016/s0140-6736(20)31604-4
[18]
Nugraha, J., Permatasari, C.A., Fitriah, M., Tambunan, B.A. and Fuadi, M.R. (2022) Kinetics of Anti-SARS-CoV-2 Responses Post Complete Vaccination with CoronaVac: A Prospective Study in 50 Health Workers. JournalofPublicHealthResearch, 11. https://doi.org/10.1177/22799036221104173
[19]
World Health Organization (2022) The Sinopharm COVID-19 Vaccine: What You Need to Know. https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
[20]
Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., et al. (2021) Efficacy of the ChAdOx1 nCOV-19 Covid-19 Vaccine against the B.1.351 Variant. NewEnglandJournalofMedicine, 384, 1885-1898. https://doi.org/10.1056/nejmoa2102214
[21]
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., et al. (2021) Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. NewEnglandJournalofMedicine, 384, 1899-1909. https://doi.org/10.1056/nejmoa2103055
[22]
van Oosterhout, C., Hall, N., Ly, H. and Tyler, K.M. (2021) COVID-19 Evolution during the Pandemic—Implications of New SARS-CoV-2 Variants on Disease Control and Public Health Policies. Virulence, 12, 507-508. https://doi.org/10.1080/21505594.2021.1877066
[23]
Ricke, D.O. (2021) Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies. FrontiersinImmunology, 12, Article 640093. https://doi.org/10.3389/fimmu.2021.640093